| Indication |
Phase |
Sample Size |
Study Design |
| Chronic Kidney Disease |
2 |
40 |
Multi-center,
randomized, double-blind, placebo-controlled, dose escalation
study |
| Chronic Kidney Disease |
4 |
300 |
Registry |
| Chronic Kidney Disease |
2 |
150 |
Multi-center, double-blind, placebo-controlled study |
| Hypoactive Sexual Desire Disorder |
3 |
600 |
Randomized
discontinuation study containing an open-label, flexible dose
period followed by a double-blind, randomized, placebo-controlled
period |
| End-Stage Renal Disease |
1 |
12 |
Open-label,
non-randomized, non-comparative study |
